相关实验视频

Updated: Sep 18, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在NKTCL中,YTHDF2通过调节SLC16A9的m6A修饰来调节氨酸 (ADM) 耐药性

Meng Dong¹, Xudong Zhang¹, Zeyuan Wang¹

¹Department of Oncology, The First Affiliated Hospital of Zhengzhou University 450000, Zhengzhou, PR China.

Translational oncology

|June 24, 2025

概括

自然杀手/T细胞淋巴瘤 (NKTCL) 耐药性与SLC16A9.9有关. YTHDF2蛋白通过m6A修饰来调节SLC16A9,为克服NKTCL中的阿德里亚米辛耐药性提供了一个新的治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

自然杀手/T细胞淋巴瘤 (NKTCL) 是一种具有攻击性的癌症,以抗化学疗法,特别是像阿德里亚米辛 (ADM) 这样的类人环素耐药性而闻名.
在NKTCL中驱动ADM耐药性的精确分子机制仍然不完全理解.

研究的目的:

研究YTHDF2在调节SLC16A9mRNA稳定性的作用.
确定YTHDF2-SLC16A9相互作用对NKTCL内的ADM耐药性的影响.

主要方法:

检查SLC16A9表达的变化,以应对不同的ADM度.
通过过度表达和淘汰技术操纵SLC16A9和YTHDF2表达水平.
分析了m6A修饰水平,以确认YTHDF2通过m6A通路对SLC16A9的调节,并通过体内实验验证实.

主要成果:

过度表达SLC16A9增加了ADM耐药性,而它的淘汰提高了敏感性.
ADM治疗降低了SLC16A9mRNA上的m6A修饰,减少了YTHDF2结合,并增加了SLC16A9的表达.
过度表达YTHDF2降低了SLC16A9的表达,并提高了ADM的敏感性;YTHDF2的淘汰具有相反的效果.
在体内研究证实,SLC16A9敲击降低了瘤生长,改善了ADM的敏感性.

结论:

YTHDF2通过控制SLC16A9.9的m6A修改直接调节NKTCL中的ADM电阻.
YTHDF2-m6A-SLC16A9轴呈现了一个潜在的新型治疗策略,用于对抗NKTCL中的化疗耐药性.

关键词:

在ADM中,阻力是ADM的阻力.在NKTCL中,它是NKTCL.在SLC16A9A9中,它是SLC16A9A9.这就是YTHDF2的原因.m6A 一个很好的.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...